Using a promiscuous inhibitor to uncover cancer drug targets

Scientists at Harvard Medical School and the Dana-Farber Cancer Institute have developed a method that exploits the multitargeted nature of a chemical inhibitor to pinpoint vulnerabilities within cancer cells.

Probing the function of key proteins

"Kinase inhibitor" drugs, which target a class of enzymes that are crucial to keep cells running, make up one of the great success stories of modern medicine.

page 2 from 2